# Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

> **NCT04716998** · PHASE1,PHASE2 · COMPLETED · sponsor: **BonusBio Group Ltd** · enrollment: 50 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** MesenCure

## Key facts

- **NCT ID:** NCT04716998
- **Lead sponsor:** BonusBio Group Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-14
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04716998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04716998, "Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04716998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*